Drug intelligence / Profile preview

DCB-206

Development stage: Preclinical
Lead developer: Dewcell Biotherapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

DCB-206 is an investigational cell therapy candidate developed by Dewcell Biotherapeutics, designed as an artificial platelet product for use in blood transfusion and regenerative medicine. The therapy is likely produced using Dewcell's proprietary platform technologies, such as en-aPLT™ (engineered artificial platelet production platform) or i-aPLP™ (iPSC-derived artificial platelet-like particle), which aim to generate functional, scalable, and donor-independent platelet substitutes. DCB-206 is intended to mimic the physiological role of natural platelets in hemostasis and wound healing, providing a therapeutic option for patients requiring platelet transfusions or regenerative treatments to support tissue repair.

Beyond the preview

Go deeper on DCB-206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DCB-206.

Explore the full profile